Skip to main content

JOHNSON & JOHNSON

For the period ended Mar 11, 2026. Filed Mar 11, 2026.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Mar 11, 2026 · Filed Mar 11, 2026

JNJ$276.22+1.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

oPreliminary Proxy Statement
oConfidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ýDefinitive Proxy Statement
oDefinitive Additional Materials
oSoliciting Material under § 240.14a-12

Johnson & Johnson

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than Registrant)

Payment of Filing Fee (Check all boxes that apply):

ýNo fee required.
oFee paid previously with preliminary materials.
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-(6)(i)(4) and 0-11.

Notice of Annual Meeting & Proxy Statement

TimeThursday, April 23, 202610:00 a.m., Eastern TimeLocationwww.virtualshareholdermeeting.com/JNJ2026Record DateFebruary 24, 2026

Items of Business

ProposalsBoardRecommendationPage
Elect the 12 nominees named in this Proxy Statement to serve as Directors for the coming year.FOR each Director nomineePage 12
Vote, on an advisory basis, to approve named executive officer compensation.FORPage 48
Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2026.FORPage 116
Vote on the shareholder proposal contained in this Proxy Statement, if properly presented at the Annual Meeting.AGAINSTPage 119
Transact such other matters as may properly come before the Annual Meeting and at any adjournment or postponement of the Annual Meeting.

You are invited to attend the Annual Meeting of Shareholders of Johnson & Johnson.

The 2026 Annual Meeting will be held online in a virtual format.

You or your proxyholder will be able to attend the 2026 Annual Meeting online, vote and submit questions by visitingwww.virtualshareholdermeeting.com/JNJ2026 and using the 16-digit control number included on your notice, on your proxy card or in the voting instructions that accompanied your proxy materials.

By order of the Board of Directors,

Marc Larkins

Worldwide Vice President, Corporate Governance

Corporate Secretary

March 11, 2026

VotingYou are eligible to vote if you were a shareholder of record at the close of business on February 24, 2026. Ensure that your shares are represented at the meeting by voting in one of several ways:
To vote via the internet prior to the meeting, go to the website listed on your proxy card or notice.
To vote by phone, call the telephone number specified on your proxy card or on the website listed on your notice.
If you received paper copies of your proxy materials, mark, sign, date and return your proxy card in the postage-paid envelope provided to vote by mail.
Whether or not you plan to attend the Annual Meeting, we call on you to vote and submit your proxy in advance of the meeting by using one of the methods described above.
2026 Proxy Statement1

Important notice regarding the availability of Proxy Materials for the

Annual Meeting of Shareholders of Johnson & Johnson

to be held on April 23, 2026.

The Proxy Statement and Annual Report to Shareholders are available at

www.investor.jnj.com/asm

2

Table of contents

5A message from our Lead Independent Director
6Living into Our Credo
82026 Proxy Statement – summary
12Board of Directors and corporate governance
ITEM 1: Election of Directors
122026 Board nominees
13Director nomination process and Board refreshment
15Nominee skills, expertise and background
16Board nominee biographies
22Corporate governance
22Corporate governance highlights
24Board structure and operations
33Oversight of our Company
38Shareholder engagement
39Related person transactions and Director independence
42Director compensation
42Fiscal 2026 non-employee Director compensation
42Fiscal 2025 non-employee Director compensation
44Director compensation policies and practices
44Deferred fee plan for Directors
44Additional arrangements
45Stock ownership guidelines for non-employee Directors
45Stock ownership information
45Security ownership of certain beneficial owners, officers and Directors
48Compensation of executives
ITEM 2: Advisory vote to approve named executive officer compensation
49A message from our Compensation & Benefits Committee
50Compensation Committee report
51Compensation discussion and analysis
522025 Executive compensation summary
572025 Executive compensation
64Compensation decisions for 2025 performance
66NEO performance and compensation summaries
70Executive compensation decision process
75Additional information concerning executive compensation
77Compensation policies and practices
78Compensation decisions for 2024 performance
79Reconciliation of non-GAAP performance measures
82Executive compensation tables
82Reconciliation of our CEO's 2025 total direct compensation to the 2025 summary compensation table
852025 Summary compensation table
912025 Grants of plan-based awards
942025 Outstanding equity awards at fiscal year-end
972025 Option exercises and stock vested
972025 Pension benefits
992025 Non-qualified deferred compensation
1022025 Potential payments upon termination
105Ratio of the annual total compensation of the median-paid employee to the CEO
106Pay versus performance
114Equity grant practices
115Audit matters
115Audit Committee report
ITEM 3: Ratification of appointment of independent registered public accounting firm
117Selection and engagement of audit firm
117Audit and non-audit fees
118Pre-approval of audit and non-audit services
ITEM 4: Shareholder proposal — independent board chair
122Other information
128Non-GAAP reconciliation
Index of frequently requested information (alphabetical)
123Annual Meeting attendance22Corporate governance highlights59Long-term incentives102Severance benefits
77Anti-pledging, hedging policy36Cybersecurity123Notice and access38Shareholder engagement
117Auditor fees16Director biographies57Pay for performance119Shareholder proposal
117Auditor tenure40Director independence72Peer group comparisonsStock ownership requirements:
14Board and Committees evaluation23Director overboarding policy64Perquisites45for non-employee Directors
24Board leadership structure13Director qualifications37Political spending oversight77for executive officers
33Board meeting attendance78Exec. comp. recoupment policies35Product quality and patient safety37Sustainability and environmental
105CEO pay ratio37Human capital management22Proxy accessstewardship
66CEO performance evaluation26Lead Independent Director duties39Related person transactions122Voting
71Compensation consultantand responsibilities33Risk oversight127Websites and resources
52Compensation summary
2026 Proxy Statement3

Our Credo

We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to provide value, reduce our costs and maintain reasonable prices. Customers' orders must be serviced promptly and accurately. Our business partners must have an opportunity to make a fair profit.

We are responsible to our employees who work with us throughout the world. We must provide an inclusive work environment where each person must be considered as an individual. We must respect their diversity and dignity and recognize their merit. They must have a sense of security, fulfillment and purpose in their jobs. Compensation must be fair and adequate and working conditions clean, orderly and safe. We must support the health and well-being of our employees and help them fulfill their family and other personal responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide highly capable leaders and their actions must be just and ethical.

We are responsible to the communities in which we live and work and to the world community as well. We must help people be healthier by supporting better access and care in more places around the world. We must be good citizens - support good works and charities, better health and education, and bear our fair share of taxes. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources.

Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed, investments made for the future and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return.

4

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.